Dexlan (Dexlansoprazole) belongs to the class of drugs known as proton pump inhibitors. Proton pump inhibitors inhibit the secretion of hydrogen ions in the stomach by inhibiting the (H+/K+)ATPase enzyme at the secretory surface of the gastric parietal cell, resulting in potent inhibition of gastric acid secretion with prolonged elevation of intragastric pH. Dexlan is a novel modified release formulation of Dexlansoprazole, an enantiomer of Lansoprazole, which employs an innovative Dual Delayed Release (DDR) technology designed to prolong the plasma dexlansoprazole concentration vs.time profile and provide extended duration of acid suppression with once-daily dosing. 

1. Healing of all grades of erosive esophagitis (EE) 
2. Maintaining healing of erosive esophagitis 
3. Heart burn associated with non-erosive gastroesophageal reflux disease (GERD) 

Patients taking concomitant Warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. 

Adverse events are rarely seen; such as diarrhea, abdominal pain, nausea, vomiting, flatulence etc. 

Dexlansoprazole is considered a pregnancy Category B medication. This means that Dexlansoprazole is probably safe for use during pregnancy, although the full risks are currently unknown. 

Safety and effectiveness of Dexlansoprazole in pediatric patients (less than 18 years of age) have not been established. 

There have been no reports of significant overdose of Dexlansoprazole. It is not expected to be removed from the circulation by hemodialysis. If an overdose occurs, treatment should be symptomatic and supportive. 

Store in a cool (below 30°C) and dry place, protect from light. Keep out of reach of children. 

Dexlan MUPS-30 Tablet: Each box contains 5x10 tablets in Alu-Alu blister pack.